Details of the Drug

General Information of Drug (ID: DMN1EFR)

Drug Name

RhGDF-5

Synonyms

MD-05; MD-06; MD-07; MD-08; RhGDF-5 (bone regeneration); MP52 (BCP carrier, bone regeneration), BioPharm/Scil; RhGDF-5 (bone regeneration), Scil/Medtronic; RhGDF-5 (implantable bone substitute), BioPharm/Scil; MP52 (beta-tricalciumphosphate carrier, bone regeneration), BioPharm/Scil

Indication

Disease Entry	ICD 11	Status	REF
Periodontal disease	DA0C	Phase 2	[1]
------------------------------------------------------------------------------------

Cross-matching ID

TTD ID: D0V4IQ

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Growth/differentiation factor 5 (GDF-5)	TT37XV9	GDF5_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01124006) A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration. U.S. National Institutes of Health.
2	Superior effect of MD05, beta-tricalcium phosphate coated with recombinant human growth/differentiation factor-5, compared to conventional bone substitutes in the rat calvarial defect model. J Periodontol. 2006 Sep;77(9):1582-90.